Goldman Sachs says this little-known biotech stock can jump more than 50%

Home » Blog » Goldman Sachs says this little-known biotech stock can jump more than 50%

December 20, 2022January 9, 2023

Analyst Chris Shibutani initiated the stock with a buy rating, saying the company has a promising new oral treatment in development for plaque psoriasis.

Previous PostFTX founder Bankman-Fried sent back to Bahamas jail in day of courtroom chaosNext PostThis unusual media stock is a top 2023 play from Morgan Stanley because of growing F1 popularity

Latest Articles

Stocks making the biggest moves after hours: Nvidia, Snowflake and more
Stocks making the biggest moves midday: Target, Nvidia, AppLovin, Williams-Sonoma and more
Stocks making the biggest moves premarket: Target, Dolby Laboratories, Nio, Netflix and more
U.S. ‘industrial renaissance’ is fueling a rebound in fundraising, Apollo CEO Marc Rowan says
Nvidia says it will sell more of its next-generation Blackwell chips than previously anticipated
Snowflake shares pop 19% on earnings and revenue beat
Business spending on AI surged 500% this year to $13.8 billion, says Menlo Ventures
Billionaire Gautam Adani charged in New York with massive fraud, bribery scheme
Asia markets mostly fall as investors assess Nvidia results, Adani charges
Nvidia nearly doubles revenue on strong AI demand